Skip to main content
. Author manuscript; available in PMC: 2022 Mar 30.
Published in final edited form as: Circulation. 2021 Jan 22;143(13):1302–1316. doi: 10.1161/CIRCULATIONAHA.120.050432

Figure 2. Enhancer activity in IPSC-Derived Cardiomyocytes (IPSC-CMs).

Figure 2.

A luciferase reporter assay was used to test for enhancer activity in IPSC-CMs. The position of candidate enhancers is shown along the top in colored boxes. The clusters in Figure 1 were evaluated as smaller regions. A. Regions from 4 of 5 candidate enhancer regions demonstrated activity in IPSC-CMs, with the highest activity for MYH7 C3. B. Five of six candidate enhancer regions for LMNA showed activity in IPSC-CMs, with the highest being LMNA-C5. These data indicate the candidate MYH7 and LMNA enhancers have activity in human cardiomyocyte-like cells. Data is displayed as fold change to a negative control 500bp genomic desert region with mean ±SD. Expression was measured in an average of 32 assays per construct over four independent differentiations. Significance vs negative control determined by nonparametric one-way ANOVA with Dunn’s multiple comparisons correction. *<0.03, **<0.0021, ****<0.0001.